company background image
FAGR logo

Fagron ENXTBR:FAGR 株式レポート

最終価格

€17.84

時価総額

€1.3b

7D

-0.4%

1Y

14.4%

更新

01 Jul, 2024

データ

会社財務 +

Fagron NV

ENXTBR:FAGR 株式レポート

時価総額:€1.3b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

FAGR 株式概要

ファグロンNVは、世界中の病院、薬局、診療所、患者に個別化された医薬品ケアを提供する調剤会社である。

FAGR ファンダメンタル分析
スノーフレーク・スコア
評価3/6
将来の成長2/6
過去の実績3/6
財務の健全性4/6
配当金2/6

Fagron NV 競合他社

価格と性能

の歴代最高値、変動、値下がりまとめFagron
過去の株価
現在の株価€17.84
52週高値€19.06
52週安値€15.30
ベータ0.26
11ヶ月の変化-5.21%
3ヶ月変化4.33%
1年変化14.36%
33年間の変化-3.31%
5年間の変化9.72%
IPOからの変化77.16%

最新ニュース

Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 07
Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year

The Returns At Fagron (EBR:FAGR) Aren't Growing

Apr 17
The Returns At Fagron (EBR:FAGR) Aren't Growing

Is Fagron (EBR:FAGR) A Risky Investment?

Mar 15
Is Fagron (EBR:FAGR) A Risky Investment?

Recent updates

Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 07
Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year

The Returns At Fagron (EBR:FAGR) Aren't Growing

Apr 17
The Returns At Fagron (EBR:FAGR) Aren't Growing

Is Fagron (EBR:FAGR) A Risky Investment?

Mar 15
Is Fagron (EBR:FAGR) A Risky Investment?

Earnings Tell The Story For Fagron NV (EBR:FAGR)

Feb 18
Earnings Tell The Story For Fagron NV (EBR:FAGR)

Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly

Aug 11
Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly

Be Wary Of Fagron (EBR:FAGR) And Its Returns On Capital

Jun 10
Be Wary Of Fagron (EBR:FAGR) And Its Returns On Capital

Fagron (EBR:FAGR) Has Announced That It Will Be Increasing Its Dividend To €0.175

May 12
Fagron (EBR:FAGR) Has Announced That It Will Be Increasing Its Dividend To €0.175

An Intrinsic Calculation For Fagron NV (EBR:FAGR) Suggests It's 30% Undervalued

Apr 20
An Intrinsic Calculation For Fagron NV (EBR:FAGR) Suggests It's 30% Undervalued

Is Fagron (EBR:FAGR) A Risky Investment?

Apr 02
Is Fagron (EBR:FAGR) A Risky Investment?

Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly

Oct 14
Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly

Return Trends At Fagron (EBR:FAGR) Aren't Appealing

Jun 04
Return Trends At Fagron (EBR:FAGR) Aren't Appealing

Fagron (EBR:FAGR) Is Paying Out A Larger Dividend Than Last Year

May 13
Fagron (EBR:FAGR) Is Paying Out A Larger Dividend Than Last Year

Is Fagron (EBR:FAGR) Using Too Much Debt?

Apr 13
Is Fagron (EBR:FAGR) Using Too Much Debt?

Slowing Rates Of Return At Fagron (EBR:FAGR) Leave Little Room For Excitement

Feb 16
Slowing Rates Of Return At Fagron (EBR:FAGR) Leave Little Room For Excitement

Fagron (EBR:FAGR) Has A Pretty Healthy Balance Sheet

Nov 18
Fagron (EBR:FAGR) Has A Pretty Healthy Balance Sheet

Fagron (EBR:FAGR) Is Experiencing Growth In Returns On Capital

Sep 25
Fagron (EBR:FAGR) Is Experiencing Growth In Returns On Capital

Are Investors Undervaluing Fagron NV (EBR:FAGR) By 45%?

Aug 30
Are Investors Undervaluing Fagron NV (EBR:FAGR) By 45%?

Fagron NV (EBR:FAGR) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 08
Fagron NV (EBR:FAGR) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Is Fagron (EBR:FAGR) A Risky Investment?

Jun 15
Is Fagron (EBR:FAGR) A Risky Investment?

Fagron NV (EBR:FAGR) Shares Could Be 49% Below Their Intrinsic Value Estimate

May 29
Fagron NV (EBR:FAGR) Shares Could Be 49% Below Their Intrinsic Value Estimate

The Returns At Fagron (EBR:FAGR) Aren't Growing

May 03
The Returns At Fagron (EBR:FAGR) Aren't Growing

Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly

Mar 08
Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly

Is Fagron NV (EBR:FAGR) A Smart Choice For Dividend Investors?

Feb 22
Is Fagron NV (EBR:FAGR) A Smart Choice For Dividend Investors?

The Returns At Fagron (EBR:FAGR) Provide Us With Signs Of What's To Come

Jan 31
The Returns At Fagron (EBR:FAGR) Provide Us With Signs Of What's To Come

Is Fagron NV (EBR:FAGR) Popular Amongst Institutions?

Jan 14
Is Fagron NV (EBR:FAGR) Popular Amongst Institutions?

How Much Does Fagron's (EBR:FAGR) CEO Make?

Dec 27
How Much Does Fagron's (EBR:FAGR) CEO Make?

Are Investors Undervaluing Fagron NV (EBR:FAGR) By 25%?

Dec 14
Are Investors Undervaluing Fagron NV (EBR:FAGR) By 25%?

Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly

Nov 30
Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly

Should You Be Excited About Fagron NV's (EBR:FAGR) 26% Return On Equity?

Nov 17
Should You Be Excited About Fagron NV's (EBR:FAGR) 26% Return On Equity?

Is Fagron (EBR:FAGR) Using Too Much Debt?

Aug 23
Is Fagron (EBR:FAGR) Using Too Much Debt?

Why Fagron NV (EBR:FAGR) Looks Like A Quality Company

Aug 10
Why Fagron NV (EBR:FAGR) Looks Like A Quality Company

Should Fagron (EBR:FAGR) Be Disappointed With Their 64% Profit?

Jul 28
Should Fagron (EBR:FAGR) Be Disappointed With Their 64% Profit?

Will Fagron (EBR:FAGR) Multiply In Value Going Forward?

Jul 14
Will Fagron (EBR:FAGR) Multiply In Value Going Forward?

What Kind Of Shareholder Owns Most Fagron NV (EBR:FAGR) Stock?

Jun 30
What Kind Of Shareholder Owns Most Fagron NV (EBR:FAGR) Stock?

株主還元

FAGRBE HealthcareBE 市場
7D-0.4%-1.0%-2.4%
1Y14.4%-2.4%2.2%

業界別リターン: FAGR過去 1 年間で-0.4 % の収益を上げたBelgian Healthcare業界を上回りました。

リターン対市場: FAGR過去 1 年間で2.5 % の収益を上げたBelgian市場を上回りました。

価格変動

Is FAGR's price volatile compared to industry and market?
FAGR volatility
FAGR Average Weekly Movement2.9%
Healthcare Industry Average Movement5.0%
Market Average Movement3.6%
10% most volatile stocks in BE Market6.6%
10% least volatile stocks in BE Market2.5%

安定した株価: FAGR過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: FAGRの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
19903,282Rafael Padillawww.fagron.com

ファグロンNVは医薬品コンパウンド会社で、世界中の病院、薬局、診療所、患者に個別化された医薬品ケアを提供している。事業セグメントは3つ:エッセンシャルズ、ブランド、配合サービス。同社はまた、医薬品調合用のコンセプト、車両、製剤を革新している。同社の製品には、あらゆるカプセル製剤を配合するための賦形剤ラインであるDiluCap、免疫反応の調節に役立つImuno TF Complex、色素沈着症のための天然植物性複合体であるPigmerise、初回通過代謝を回避し、胃腸浸食を防ぐためのPentravanなどがある;NourisilMD、傷跡の予防とケロイドの治療のための第一選択薬、Neogen、ヘアケア製品、脱毛症の治療に使用されるTrichoConcept、基本的なスキンケア、複合医薬品治療、個別の皮膚科治療に使用されるFagron Advanced Derma、医薬品の安定性、投与量の安定性、患者の快適性を提供するSyrSpend SF。さらに、同社はファグロンアカデミーを通じて、処方者や薬剤師に教育・研修プログラムを提供している。同社は以前Arseus NVとして知られていたが、2015年1月にFagron NVに社名を変更した。Fagron NVは1990年に設立され、ベルギーのナザレを拠点としている。

Fagron NV 基礎のまとめ

Fagron の収益と売上を時価総額と比較するとどうか。
FAGR 基礎統計学
時価総額€1.30b
収益(TTM)€70.55m
売上高(TTM)€762.99m

18.5x

PER(株価収益率

1.7x

P/Sレシオ

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
FAGR 損益計算書(TTM)
収益€762.99m
売上原価€430.38m
売上総利益€332.61m
その他の費用€262.07m
収益€70.55m

直近の収益報告

Dec 31, 2023

次回決算日

Aug 01, 2024

一株当たり利益(EPS)0.97
グロス・マージン43.59%
純利益率9.25%
有利子負債/自己資本比率69.7%

FAGR の長期的なパフォーマンスは?

過去の実績と比較を見る

配当金

1.7%

現在の配当利回り

31%

配当性向